136 related articles for article (PubMed ID: 38657345)
1. Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study).
Orbach D; Carton M; Khadir SK; Feuilly M; Kurtinecz M; Phil D; Vokuhl C; Koscielniak E; Pierron G; Lemelle L; Sparber-Sauer M
ESMO Open; 2024 May; 9(5):103006. PubMed ID: 38657345
[TBL] [Abstract][Full Text] [Related]
2. Larotrectinib versus historical standard of care in patients with infantile fibrosarcoma: protocol of EPI-VITRAKVI.
Carton M; Del Castillo JP; Colin JB; Kurtinecz M; Feuilly M; Pierron G; Arvis P; Khadir SK; Sparber-Sauer M; Orbach D
Future Oncol; 2023 Aug; 19(24):1645-1653. PubMed ID: 37133249
[TBL] [Abstract][Full Text] [Related]
3. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
[TBL] [Abstract][Full Text] [Related]
4. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T
Ann Oncol; 2019 Nov; 30 Suppl 8():viii31-viii35. PubMed ID: 32223937
[TBL] [Abstract][Full Text] [Related]
5. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
6. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T
Ann Oncol; 2019 Nov; 30(Suppl_8):viii31-viii35. PubMed ID: 31738425
[TBL] [Abstract][Full Text] [Related]
7. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S
Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data.
Bokemeyer C; Paracha N; Lassen U; Italiano A; Sullivan SD; Marian M; Brega N; Garcia-Foncillas J
JCO Precis Oncol; 2023 Jan; 7():e2200436. PubMed ID: 36689698
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies.
Orbach D; Sparber-Sauer M; Laetsch TW; Minard-Colin V; Bielack SS; Casanova M; Corradini N; Koscielniak E; Scheer M; Hettmer S; Bisogno G; Hawkins DS; Ferrari A
Eur J Cancer; 2020 Sep; 137():183-192. PubMed ID: 32784118
[TBL] [Abstract][Full Text] [Related]
10. Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report.
Corral Sánchez MD; Galán Gómez V; Sastre Urgelles A; Plaza López de Sabando D; Rubio Aparicio P; Martínez Martínez L; Alonso Gamarra E; Pozo Kreilinger JJ; Regojo Zapata RM; López Gutiérrez JC; Antolín Alvarado E; Gómez Martín F; Sánchez Torres AM; Marín Manzano E; González Del Valle L; Pérez-Martínez A
Pediatr Hematol Oncol; 2021 Aug; 38(5):504-509. PubMed ID: 33622165
[TBL] [Abstract][Full Text] [Related]
11. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
Hong DS; DuBois SG; Kummar S; Farago AF; Albert CM; Rohrberg KS; van Tilburg CM; Nagasubramanian R; Berlin JD; Federman N; Mascarenhas L; Geoerger B; Dowlati A; Pappo AS; Bielack S; Doz F; McDermott R; Patel JD; Schilder RJ; Tahara M; Pfister SM; Witt O; Ladanyi M; Rudzinski ER; Nanda S; Childs BH; Laetsch TW; Hyman DM; Drilon A
Lancet Oncol; 2020 Apr; 21(4):531-540. PubMed ID: 32105622
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
[TBL] [Abstract][Full Text] [Related]
13. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies.
Pollack M; Keating K; Wissinger E; Jackson L; Sarnes E; Cuffel B
Curr Med Res Opin; 2021 Jan; 37(1):59-70. PubMed ID: 33148054
[TBL] [Abstract][Full Text] [Related]
14. The impact of local control in the treatment of children with advanced infantile and adult-type fibrosarcoma: Experience of the cooperative weichteilsarkom studiengruppe (CWS).
Sparber-Sauer M; Vokuhl C; Seitz G; Stegmaier S; Hallmen E; von Kalle T; Scheer M; Münter M; Bielack SS; Ladenstein R; Niggli F; Ljungman G; Fuchs J; Klingebiel T; Koscielniak E;
J Pediatr Surg; 2020 Sep; 55(9):1740-1747. PubMed ID: 31753608
[TBL] [Abstract][Full Text] [Related]
15. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
Kummar S; Berlin J; Mascarenhas L; van Tilburg CM; Geoerger B; Lassen UN; Schilder RJ; Turpin B; Nanda S; Keating K; Childs BH; Chirila C; Laetsch TW; Hyman DM; Drilon A; Hong DS
Curr Probl Cancer; 2021 Dec; 45(6):100734. PubMed ID: 33865615
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategies and clinical evolution of patients with infantile fibrosarcoma: a unique paediatric case series.
Corral Sánchez MD; Jiménez Carrascoso R; Rubio Aparicio P; Plaza López de Sabando D; Sastre Urgelles A; Pozo-Kreilinger JJ; López Gutiérrez JC; Gómez Cervantes M; Ortiz Cruz EJ; Pérez-Martínez A
Clin Transl Oncol; 2023 Nov; 25(11):3307-3311. PubMed ID: 37097530
[TBL] [Abstract][Full Text] [Related]
17. Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion-Positive Solid Tumors.
Bokemeyer C; Vassal G; Italiano A; De La Cuesta E; Hiemeyer F; Fellous M; Marian M
JCO Precis Oncol; 2021; 5():. PubMed ID: 34568715
[TBL] [Abstract][Full Text] [Related]
18. Limb salvage of an infant with infantile fibrosarcoma using TRK inhibitor larotrectinib.
Sahni S; Rastogi S; Yadav R; Barwad A
Ecancermedicalscience; 2023; 17():1575. PubMed ID: 37533946
[TBL] [Abstract][Full Text] [Related]
19. The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma.
Suh K; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Manag Care Spec Pharm; 2022 Jun; 28(6):622-630. PubMed ID: 35362337
[No Abstract] [Full Text] [Related]
20. Larotrectinib: First Global Approval.
Scott LJ
Drugs; 2019 Feb; 79(2):201-206. PubMed ID: 30635837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
